Short Interest in Vincerx Pharma, Inc. (NASDAQ:VINC) Increases By 76.9%

Vincerx Pharma, Inc. (NASDAQ:VINC) was the target of a large increase in short interest in February. As of February 28th, there was short interest totalling 191,900 shares, an increase of 76.9% from the February 13th total of 108,500 shares. Based on an average daily volume of 804,500 shares, the short-interest ratio is presently 0.2 days. Currently, 10.0% of the shares of the stock are short sold.

Vincerx Pharma Stock Up 1.0 %

Shares of VINC opened at $0.82 on Friday. Vincerx Pharma has a 12-month low of $0.75 and a 12-month high of $151.80. The business has a 50-day simple moving average of $1.82 and a two-hundred day simple moving average of $6.27. The stock has a market cap of $1.84 million, a PE ratio of -0.04 and a beta of 1.43.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.